Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mandy Mynhier

Physician Assistant, Medical Georgetown, KY Physician Assistant

NPI 1285829556 CMS profile 10652944

200 Bevins Ln Ste A, Georgetown, KY 40324

Open in the dashboard

General payments

$6,881

423 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mandy Mynhier of Georgetown, KY is reported in the CMS Open Payments database as having received $6,881 across 423 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $855 48
2024 General $1,202 62
2023 General $1,673 93
2022 General $1,533 102
2021 General $1,619 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mandy Mynhier
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Mandy Mynhier were reported at $855. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Mandy Mynhier Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,619 $156 $41–$563 $132
2022 $1,533 $185 $55–$649 $149
2023 $1,673 $199 $58–$717 $160
2024 $1,202 $206 $62–$740 $164
2025 $855 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $814 59 payments
  2. Lilly USA, LLC $665 43 payments
  3. AbbVie, Inc. $514 34 payments
  4. Merck Sharp & Dohme Corporation $456 27 payments
  5. Novo Nordisk Inc $436 32 payments
  6. Astellas Pharma US Inc $364 16 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $337 24 payments
  8. Novartis Pharmaceuticals Corporation $324 20 payments
  9. AstraZeneca Pharmaceuticals LP $263 14 payments
  10. Amgen Inc. $210 12 payments
  11. Other $2,496 142 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,781 422 payments
  2. Education $100 1 payment
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $771 56 payments
  2. VERQUVO $469 28 payments
  3. UBRELVY $445 30 payments
  4. XIFAXAN $337 24 payments
  5. MOUNJARO $307 19 payments
  6. BELSOMRA $282 18 payments
  7. QULIPTA $253 17 payments
  8. STEGLATRO $214 14 payments
  9. TRINTELLIX $210 11 payments
  10. Ozempic $207 18 payments
  11. Other $4,890 293 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 95 drugs

Part D claims

3,633

Median for Physician Assistant: 241

Drug cost

$274,870

Median for Physician Assistant: $4,110

Branded share of claims

17.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 40 $55,100
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $45,820
Mounjaro Tirzepatide Brand 32 $33,491
Jardiance Empagliflozin Brand 31 $23,449
Januvia Sitagliptin Phosphate Brand 24 $21,271
Eliquis Apixaban Brand 33 $21,269
Rybelsus Semaglutide Brand 11 $14,211
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 11 $12,099
Linzess Linaclotide Brand 15 $10,623
Tresiba Flextouch U-100 Insulin Degludec Brand 12 $6,385

The 10 drugs with the highest cost, of 95 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$25,499

Of which drugs: $588

Medicare patients

181

Average age 73

Services billed

2,172

105 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 43%
Diabetes 24%
Chronic kidney disease 20%
Ischemic heart disease 18%
Cancer 13%
Atrial fibrillation 12%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 21 1,524 $137

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $97
$97 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $92
$92 — —
QULIPTA
  • AbbVie, Inc. $89
$89 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $80
$80 — —
Auvelity
  • Axsome Therapeutics, Inc. $75
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

423 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record